Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies

Tanis Jill Ferman, Glenn E. Smith, Kejal M Kantarci, Bradley F Boeve, V. Shane Pankratz, Dennis W Dickson, Neill R Graff Radford, Zbigniew K Wszolek, Jay A Van Gerpen, Ryan Uitti, Otto D Pedraza, Melissa E Murray, Jeremiah Aakre, Joseph E Parisi, David S Knopman, Ronald Carl Petersen

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Objective: To determine the rate of progression of mild cognitive impairment (MCI) to dementia with Lewy bodies (DLB). Methods: We followed 337 patients with MCI in the Mayo Alzheimer's Disease Research Center (range 2-12 years). Competing risks survival models were used to examine the rates of progression to clinically probable DLB and Alzheimer disease (AD). A subset of patients underwent neuropathologic examination. Results: In this clinical cohort, 116 remained as MCI, while 49 progressed to probable DLB, 162 progressed to clinically probable AD, and 10 progressed to other dementias. Among nonamnestic MCI, progression rate to probable DLB was 20 events per 100 person-years and to probable AD was 1.6 per 100 person-years. Among amnestic MCI, progression rate to probable AD was 17 events per 100 person-years, and to DLB was 1.5 events per 100 person-years. In 88%of those who developed probable DLB, the baseline MCI diagnosis included attention and/or visuospatial deficits. Those who developed probable DLB were more likely to have baseline daytime sleepiness and subtle parkinsonism. In 99% of the clinically probable AD group, the baseline MCI diagnosis included memory impairment. Neuropathologic confirmation was obtained in 24 of 30 of those with clinically probable AD, and in 14 of 18 of those with clinically probable DLB.

Original languageEnglish (US)
Pages (from-to)2032-2038
Number of pages7
JournalNeurology
Volume81
Issue number23
DOIs
StatePublished - Dec 3 2013

Fingerprint

Lewy Body Disease
Alzheimer Disease
Dementia
Cognitive Dysfunction
Mild Cognitive Impairment
Parkinsonian Disorders
Alzheimer's Disease
Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. / Ferman, Tanis Jill; Smith, Glenn E.; Kantarci, Kejal M; Boeve, Bradley F; Pankratz, V. Shane; Dickson, Dennis W; Graff Radford, Neill R; Wszolek, Zbigniew K; Van Gerpen, Jay A; Uitti, Ryan; Pedraza, Otto D; Murray, Melissa E; Aakre, Jeremiah; Parisi, Joseph E; Knopman, David S; Petersen, Ronald Carl.

In: Neurology, Vol. 81, No. 23, 03.12.2013, p. 2032-2038.

Research output: Contribution to journalArticle

@article{401e5b2d84d14b4fa5a814832814c17c,
title = "Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies",
abstract = "Objective: To determine the rate of progression of mild cognitive impairment (MCI) to dementia with Lewy bodies (DLB). Methods: We followed 337 patients with MCI in the Mayo Alzheimer's Disease Research Center (range 2-12 years). Competing risks survival models were used to examine the rates of progression to clinically probable DLB and Alzheimer disease (AD). A subset of patients underwent neuropathologic examination. Results: In this clinical cohort, 116 remained as MCI, while 49 progressed to probable DLB, 162 progressed to clinically probable AD, and 10 progressed to other dementias. Among nonamnestic MCI, progression rate to probable DLB was 20 events per 100 person-years and to probable AD was 1.6 per 100 person-years. Among amnestic MCI, progression rate to probable AD was 17 events per 100 person-years, and to DLB was 1.5 events per 100 person-years. In 88{\%}of those who developed probable DLB, the baseline MCI diagnosis included attention and/or visuospatial deficits. Those who developed probable DLB were more likely to have baseline daytime sleepiness and subtle parkinsonism. In 99{\%} of the clinically probable AD group, the baseline MCI diagnosis included memory impairment. Neuropathologic confirmation was obtained in 24 of 30 of those with clinically probable AD, and in 14 of 18 of those with clinically probable DLB.",
author = "Ferman, {Tanis Jill} and Smith, {Glenn E.} and Kantarci, {Kejal M} and Boeve, {Bradley F} and Pankratz, {V. Shane} and Dickson, {Dennis W} and {Graff Radford}, {Neill R} and Wszolek, {Zbigniew K} and {Van Gerpen}, {Jay A} and Ryan Uitti and Pedraza, {Otto D} and Murray, {Melissa E} and Jeremiah Aakre and Parisi, {Joseph E} and Knopman, {David S} and Petersen, {Ronald Carl}",
year = "2013",
month = "12",
day = "3",
doi = "10.1212/01.wnl.0000436942.55281.47",
language = "English (US)",
volume = "81",
pages = "2032--2038",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies

AU - Ferman, Tanis Jill

AU - Smith, Glenn E.

AU - Kantarci, Kejal M

AU - Boeve, Bradley F

AU - Pankratz, V. Shane

AU - Dickson, Dennis W

AU - Graff Radford, Neill R

AU - Wszolek, Zbigniew K

AU - Van Gerpen, Jay A

AU - Uitti, Ryan

AU - Pedraza, Otto D

AU - Murray, Melissa E

AU - Aakre, Jeremiah

AU - Parisi, Joseph E

AU - Knopman, David S

AU - Petersen, Ronald Carl

PY - 2013/12/3

Y1 - 2013/12/3

N2 - Objective: To determine the rate of progression of mild cognitive impairment (MCI) to dementia with Lewy bodies (DLB). Methods: We followed 337 patients with MCI in the Mayo Alzheimer's Disease Research Center (range 2-12 years). Competing risks survival models were used to examine the rates of progression to clinically probable DLB and Alzheimer disease (AD). A subset of patients underwent neuropathologic examination. Results: In this clinical cohort, 116 remained as MCI, while 49 progressed to probable DLB, 162 progressed to clinically probable AD, and 10 progressed to other dementias. Among nonamnestic MCI, progression rate to probable DLB was 20 events per 100 person-years and to probable AD was 1.6 per 100 person-years. Among amnestic MCI, progression rate to probable AD was 17 events per 100 person-years, and to DLB was 1.5 events per 100 person-years. In 88%of those who developed probable DLB, the baseline MCI diagnosis included attention and/or visuospatial deficits. Those who developed probable DLB were more likely to have baseline daytime sleepiness and subtle parkinsonism. In 99% of the clinically probable AD group, the baseline MCI diagnosis included memory impairment. Neuropathologic confirmation was obtained in 24 of 30 of those with clinically probable AD, and in 14 of 18 of those with clinically probable DLB.

AB - Objective: To determine the rate of progression of mild cognitive impairment (MCI) to dementia with Lewy bodies (DLB). Methods: We followed 337 patients with MCI in the Mayo Alzheimer's Disease Research Center (range 2-12 years). Competing risks survival models were used to examine the rates of progression to clinically probable DLB and Alzheimer disease (AD). A subset of patients underwent neuropathologic examination. Results: In this clinical cohort, 116 remained as MCI, while 49 progressed to probable DLB, 162 progressed to clinically probable AD, and 10 progressed to other dementias. Among nonamnestic MCI, progression rate to probable DLB was 20 events per 100 person-years and to probable AD was 1.6 per 100 person-years. Among amnestic MCI, progression rate to probable AD was 17 events per 100 person-years, and to DLB was 1.5 events per 100 person-years. In 88%of those who developed probable DLB, the baseline MCI diagnosis included attention and/or visuospatial deficits. Those who developed probable DLB were more likely to have baseline daytime sleepiness and subtle parkinsonism. In 99% of the clinically probable AD group, the baseline MCI diagnosis included memory impairment. Neuropathologic confirmation was obtained in 24 of 30 of those with clinically probable AD, and in 14 of 18 of those with clinically probable DLB.

UR - http://www.scopus.com/inward/record.url?scp=84892407385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892407385&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000436942.55281.47

DO - 10.1212/01.wnl.0000436942.55281.47

M3 - Article

C2 - 24212390

AN - SCOPUS:84892407385

VL - 81

SP - 2032

EP - 2038

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 23

ER -